Видео ютуба по тегу Elranatamab

Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study | ASCO 2023
Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study | ASCO 2023
Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.
Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.
Elranatamab in Relapsed or Refractory Multiple Myeloma: the MagnetisMM-1 Phase 1 Trial
Elranatamab in Relapsed or Refractory Multiple Myeloma: the MagnetisMM-1 Phase 1 Trial
Elranatamab - Upcoming Myeloma Therapy
Elranatamab - Upcoming Myeloma Therapy
ELREXFIO (elranatamab) for Multiple Myeloma: Patient Story + Doctor Explains
ELREXFIO (elranatamab) for Multiple Myeloma: Patient Story + Doctor Explains
Evaluating the safety and efficacy of elranatamab in multiple myeloma
Evaluating the safety and efficacy of elranatamab in multiple myeloma
Multiple myeloma: elranatamab as a single-agent therapy compared to CAR-T therapy
Multiple myeloma: elranatamab as a single-agent therapy compared to CAR-T therapy
Elranatamab y el mieloma
Elranatamab y el mieloma
Elranatamab Induces Durable Responses for Patients with Relapsed or Refractory Multiple Myeloma
Elranatamab Induces Durable Responses for Patients with Relapsed or Refractory Multiple Myeloma
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
MagnetisMM-3: elranatamab for myeloma
MagnetisMM-3: elranatamab for myeloma
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Advancing Multiple Myeloma Care with Elranatamab | Caroline Hoang, PhD | ASH 2023
Advancing Multiple Myeloma Care with Elranatamab | Caroline Hoang, PhD | ASH 2023
Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD | #ASH25 #myeloma
MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD | #ASH25 #myeloma
Comparing elranatamab with real-world therapies in triple-class-refractory myeloma
Comparing elranatamab with real-world therapies in triple-class-refractory myeloma
Многообещающие результаты применения элранатамаба + ибердомида от MagnetisMM-30 | Аттая Суваннаса...
Многообещающие результаты применения элранатамаба + ибердомида от MagnetisMM-30 | Аттая Суваннаса...
MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma
MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma
The safety and efficacy of elranatamab in patients with R/R AL amyloidosis
The safety and efficacy of elranatamab in patients with R/R AL amyloidosis
Elranatamab + Carfilzomib: Results in Relapsed/Refractory #Myeloma | Michael Tomasson, MD | #ASH24
Elranatamab + Carfilzomib: Results in Relapsed/Refractory #Myeloma | Michael Tomasson, MD | #ASH24